Pharmabiz1d
EMA committee recommends approval of AstraZeneca’s Calquence plus chemoimmunotherapy to treat adult patients with mantle cell lymphoma
EMA committee recommends approval of AstraZeneca’s Calquence plus chemoimmunotherapy to treat adult patients with mantle cell lymphoma: Cambridge, UK Tuesday, April 1, 2025, 17: ...
PharmiWeb2d
Calquence plus chemoimmunotherapy recommended for approval in the EU by CHMP as first and only BTK inhibitor for 1st-line mantle cell lymphoma
AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...
AstraZeneca makes regulatory progress with Imfinzi, Calquence
AstraZeneca announced on Monday that it secured a US regulatory approval and a positive EU recommendation for two of its ...
FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients
The U.S. Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc's (NASDAQ:AZN) Imfinzi (durvalumab) in ...
Zacks Investment Research on MSN1d
AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication
AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer ...
AstraZeneca’s Calquence recommended for approval in EU for treatment of MCL
Calquence in combination with bendamustine and rituximab has been recommended for approval in the European Union, EU, for ...
pharmaphorum2d
Calquence approval another win for AstraZeneca in oncology
AstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next generation treatment for mantle cell lymphoma (MCL). Calquence (acalabrutinib ...
Cure Today27d
Calquence Combo May Improve Outcomes in Chronic Lymphocytic Leukemia
Calquence plus Venclexta, with or without Gazyva, significantly improved progression-free and overall survival in untreated CLL patients compared to chemoimmunotherapy. The study showed a higher ...
FDA approves new MCL treatment by AstraZeneca
WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab for the ...
pharmaphorum4d
AMPLIFY results dial up Calquence's potential in CLL
AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuster ...
Investing2d
AstraZeneca’s Calquence Nears EU Approval for Mantle Cell Lymphoma
The recommendation, announced today, is based on the ECHO Phase III trial results, which showed a notable improvement in progression-free survival when Calquence was used in combination with ...
Benzinga.com2d
FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients
Calquence combo reduced disease progression or death risk by 27% in untreated mantle cell lymphoma. Learn how to trade volatility during Q1 earnings season, live with Matt Maley on Wednesday ...